CLOPIDOGREL AND LIVER INJURY IN DIABETIC PATIENTS
Feryal H. Rada (PhD)*
Inhibition of platelet activation with antiplatelet therapy is central to the management of acute coronary syndromes (ACS), especially in cases where percutaneous coronary intervention (PCI) is performed. Clopidogrel is a second-generation thienopyridine that selectively inhibits the adenosine diphosphate (ADP) P2Y12 receptor. The present study was aimed to compare the effect of clopidogrel on hepatic function in the presence or absence of diabetic. sixty patients with coronary artery disease and twenty control subject were included in this study. All patients received a dose of 75 mg/day of clopidogrel. Of whom thirty patients were diabetic and other thirty patients were non-diabetic. Liver function tests were measured and studied for patients and control. Liver function tests in diabetic and non-diabetic coronary disease patients showed high significant elevation (P˂0.001) in mean serum total alkaline phosphatase and gamma-glutamyl transferase and significant elevation (P˂ 0.05) in mean serum direct bilirubin compared with control mean. Whereas insignificant elevation (P˃0.05) appeared in mean serum total bilirubin, alanine aminotransferase, aspartate aminotransferase, and total protein in relation to control mean. In conclusion, diabetes is not associated with an increased incidence and severity of clopidogrel induced liver injury.
Keywords: Clopidogrel; diabetic; liver function tests.
[Full Text Article]